drugset / Trial / NCT03367676
12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial aims to study the efficacy and safety of 12 weeks adjuvant docetaxel plus trastuzumab in patients with tumors ≤1cm, node-negative, HER2-positive breast cancer.
Timeline
- Start
- 2017-12-30
- Primary completion
- 2021-01-01
- Completion
- 2021-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 100 mg/m2 | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |